Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 15.64
QCOR's Cash to Debt is ranked higher than
70% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. QCOR: 15.64 )
QCOR' s 10-Year Cash to Debt Range
Min: 0.91   Max: No Debt
Current: 15.64

Equity to Asset 0.54
QCOR's Equity to Asset is ranked higher than
63% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. QCOR: 0.54 )
QCOR' s 10-Year Equity to Asset Range
Min: 0.32   Max: 0.94
Current: 0.54

0.32
0.94
F-Score: 5
Z-Score: 12.45
M-Score: 0.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 55.05
QCOR's Operating margin (%) is ranked higher than
99% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. QCOR: 55.05 )
QCOR' s 10-Year Operating margin (%) Range
Min: -2400   Max: 60.45
Current: 55.05

-2400
60.45
Net-margin (%) 36.63
QCOR's Net-margin (%) is ranked higher than
96% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. QCOR: 36.63 )
QCOR' s 10-Year Net-margin (%) Range
Min: -2400   Max: 75.52
Current: 36.63

-2400
75.52
ROE (%) 73.27
QCOR's ROE (%) is ranked higher than
99% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. QCOR: 73.27 )
QCOR' s 10-Year ROE (%) Range
Min: -229.06   Max: 122.15
Current: 73.27

-229.06
122.15
ROA (%) 39.74
QCOR's ROA (%) is ranked higher than
99% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. QCOR: 39.74 )
QCOR' s 10-Year ROA (%) Range
Min: -91.94   Max: 78.31
Current: 39.74

-91.94
78.31
ROC (Joel Greenblatt) (%) 1386.06
QCOR's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. QCOR: 1386.06 )
QCOR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1630.53   Max: 14304.25
Current: 1386.06

-1630.53
14304.25
Revenue Growth (%) 94.00
QCOR's Revenue Growth (%) is ranked higher than
98% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. QCOR: 94.00 )
QCOR' s 10-Year Revenue Growth (%) Range
Min: -12.2   Max: 171.4
Current: 94

-12.2
171.4
EBITDA Growth (%) 106.40
QCOR's EBITDA Growth (%) is ranked higher than
99% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. QCOR: 106.40 )
QCOR' s 10-Year EBITDA Growth (%) Range
Min: -62.5   Max: 117.8
Current: 106.4

-62.5
117.8
EPS Growth (%) 106.60
QCOR's EPS Growth (%) is ranked higher than
99% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. QCOR: 106.60 )
QCOR' s 10-Year EPS Growth (%) Range
Min: -52.5   Max: 106.6
Current: 106.6

-52.5
106.6
» QCOR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

QCOR Guru Trades in Q1 2013

Chuck Royce 6,400 sh (New)
Jim Simons 691,000 sh (+152.56%)
Joel Greenblatt 191,058 sh (+2.89%)
Bernard Horn 77,801 sh (unchged)
Steven Cohen 2,000 sh (-99.22%)
» More
Q2 2013

QCOR Guru Trades in Q2 2013

John Hussman 150,000 sh (New)
HOTCHKIS & WILEY 475,700 sh (New)
Chuck Royce 37,200 sh (+481.25%)
Jim Simons 894,000 sh (+29.38%)
Bernard Horn Sold Out
Steven Cohen Sold Out
Joel Greenblatt 170,683 sh (-10.66%)
» More
Q3 2013

QCOR Guru Trades in Q3 2013

Paul Tudor Jones 6,100 sh (New)
Steven Cohen 32,052 sh (New)
Chuck Royce 44,100 sh (+18.55%)
Joel Greenblatt 190,961 sh (+11.88%)
John Hussman 150,000 sh (unchged)
HOTCHKIS & WILEY Sold Out
Jim Simons 874,700 sh (-2.16%)
» More
Q4 2013

QCOR Guru Trades in Q4 2013

John Paulson 731,410 sh (New)
Steven Cohen 520,938 sh (+1525.29%)
Paul Tudor Jones 10,000 sh (+63.93%)
Joel Greenblatt 296,803 sh (+55.43%)
Chuck Royce 48,200 sh (+9.3%)
John Hussman 150,000 sh (unchged)
Paul Tudor Jones 9,500 sh (unchged)
Jim Simons 769,400 sh (-12.04%)
» More
» Details

Insider Trades

Latest Guru Trades with QCOR

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2013-12-31 New Buy0.2%$51.69 - $69.73 $ 76.9530%731410
Joel Greenblatt 2013-12-31 Add 55.43%0.14%$51.69 - $69.73 $ 76.9530%296803
John Hussman 2013-06-30 New Buy0.31%$27.31 - $47.46 $ 76.95117%150000
Joel Greenblatt 2012-12-31 Add 57.57%0.11%$19.36 - $30.06 $ 76.95201%185698
Ron Baron 2012-09-30 Sold Out 0.33%$17.83 - $57.64 $ 76.9586%0
Joel Greenblatt 2012-09-30 New Buy0.15%$17.83 - $57.64 $ 76.9586%117854
Ron Baron 2012-03-31 Add 107.64%0.12%$33.53 - $42.14 $ 76.95121%1010400
Ron Baron 2011-12-31 New Buy0.13%$26.36 - $45.59 $ 76.9596%486600
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 16.30
QCOR's P/E(ttm) is ranked higher than
87% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 28.80 vs. QCOR: 16.30 )
QCOR' s 10-Year P/E(ttm) Range
Min: 6.47   Max: 88.1
Current: 16.3

6.47
88.1
P/B 11.59
QCOR's P/B is ranked lower than
66% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. QCOR: 11.59 )
QCOR' s 10-Year P/B Range
Min: 1.87   Max: 30
Current: 11.59

1.87
30
P/S 5.95
QCOR's P/S is ranked higher than
70% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. QCOR: 5.95 )
QCOR' s 10-Year P/S Range
Min: 1.08   Max: 16.53
Current: 5.95

1.08
16.53
PFCF 14.20
QCOR's PFCF is ranked higher than
85% of the 207 Companies
in the Global Biotechnology industry.

( Industry Median: 31.10 vs. QCOR: 14.20 )
QCOR' s 10-Year PFCF Range
Min: 4.86   Max: 64
Current: 14.2

4.86
64
EV-to-EBIT 10.08
QCOR's EV-to-EBIT is ranked higher than
79% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. QCOR: 10.08 )
QCOR' s 10-Year EV-to-EBIT Range
Min: 3.5   Max: 180.6
Current: 10.08

3.5
180.6
PEG 0.17
QCOR's PEG is ranked higher than
97% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. QCOR: 0.17 )
QCOR' s 10-Year PEG Range
Min: 0.15   Max: 0.48
Current: 0.17

0.15
0.48
Shiller P/E 42.87
QCOR's Shiller P/E is ranked higher than
59% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.60 vs. QCOR: 42.87 )
QCOR' s 10-Year Shiller P/E Range
Min: 14.58   Max: 202.33
Current: 42.87

14.58
202.33

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.50
QCOR's Dividend Yield is ranked higher than
64% of the 164 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. QCOR: 1.50 )
QCOR' s 10-Year Dividend Yield Range
Min: 0.65   Max: 1.9
Current: 1.5

0.65
1.9
Dividend Payout 0.24
QCOR's Dividend Payout is ranked higher than
83% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 0.31 vs. QCOR: 0.24 )
QCOR' s 10-Year Dividend Payout Range
Min: 0.13   Max: 0.17
Current: 0.24

0.13
0.17
Yield on cost (5-Year) 1.50
QCOR's Yield on cost (5-Year) is ranked higher than
59% of the 169 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. QCOR: 1.50 )
QCOR' s 10-Year Yield on cost (5-Year) Range
Min: 0.65   Max: 1.9
Current: 1.5

0.65
1.9
Share Buyback Rate 1.70
QCOR's Share Buyback Rate is ranked higher than
97% of the 696 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. QCOR: 1.70 )
QCOR' s 10-Year Share Buyback Rate Range
Min: 3   Max: -34.7
Current: 1.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 29.37
QCOR's Price/Tangible Book is ranked lower than
86% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. QCOR: 29.37 )
QCOR' s 10-Year Price/Tangible Book Range
Min: 3.96   Max: 20.78
Current: 29.37

3.96
20.78
Price/DCF (Projected) 2.15
QCOR's Price/DCF (Projected) is ranked higher than
75% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. QCOR: 2.15 )
QCOR' s 10-Year Price/DCF (Projected) Range
Min: 1   Max: 14.07
Current: 2.15

1
14.07
Price/Median PS Value 1.37
QCOR's Price/Median PS Value is ranked higher than
56% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. QCOR: 1.37 )
QCOR' s 10-Year Price/Median PS Value Range
Min: 0.34   Max: 2.91
Current: 1.37

0.34
2.91
Price/Peter Lynch Fair Value 0.65
QCOR's Price/Peter Lynch Fair Value is ranked higher than
94% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. QCOR: 0.65 )
QCOR' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.34   Max: 1.38
Current: 0.65

0.34
1.38
Price/Graham Number 4.55
QCOR's Price/Graham Number is ranked lower than
62% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. QCOR: 4.55 )
QCOR' s 10-Year Price/Graham Number Range
Min: 1.28   Max: 4.25
Current: 4.55

1.28
4.25
Earnings Yield (Greenblatt) 9.90
QCOR's Earnings Yield (Greenblatt) is ranked higher than
78% of the 379 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. QCOR: 9.90 )
QCOR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.6   Max: 28.7
Current: 9.9

0.6
28.7
Forward Rate of Return (Yacktman) 76.80
QCOR's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. QCOR: 76.80 )
QCOR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -76   Max: 77.5
Current: 76.8

-76
77.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:QPH.Germany
Questcor Pharmaceuticals, Inc was incorporated in California in September 1992 as Cypros Pharmaceutical Corporation. In November 1999. The Company changed its name to Questcor Pharmaceuticals, Inc. The Company is a biopharmaceutical company focused on providing prescription drugs for central nervous system disorders. It is presently building a core portfolio of both marketed and development-stage products that address significant unmet medical needs. The Company seeks to develop and commercialize its own proprietary products, and is open to a range of partnering concepts in order to leverage its assets and build its portfolio. It markets H.P. Acthar Gel, an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is not indicated for, but is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral, which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It owns the worldwide rights for Acthar and the U.S. rights for Doral.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

Cgrain@google
ReplyCgrain@google - 3 months ago
QCOR has legal issues that need to be resolved.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide